Letermovir

2024年8月15-16日 苏州国际博览中心B-D馆展会背景CMC-China博览会以研发为主线，串联医药上下游，以圈友信任为纽带，帮助大家“寻找到下一个合作伙伴”，自2019年以来，我们已成功举办5届，影响力持续提升，在中国医药产业创新发展的大浪潮中，茁壮成长，已经成为国内生物医药领域大型博览会的知名品牌。企业邀约上海瀚合瑞——提供制剂项目从立项到获批的全流程药学CRO服务！欢迎莅临D馆-G05展位，现场参观，交流分享！↓↓扫描下方二维码免费报名重点项目推荐乌帕替尼缓释片规格：15mg、30mg、45mg适应症：特应性皮炎、类风湿关节炎、银屑病关节炎、溃疡性结肠炎等研发进展：小试阶段巴瑞替尼片规格：2mg、4mg适应症：类风湿关节炎、斑秃、特应性皮炎等研发进展：小试阶段非奈利酮片规格：10mg、20mg适应症：二型糖尿病相关的慢性肾病研发进展：中试阶段奥匹卡朋胶囊规格：25mg、50mg适应症：左旋多巴/卡比多巴的辅助治疗，适用于帕金森病(PD)的“off”期发作研发进展：原料药&制剂联合开发，小试阶段甲苯磺酸奥马环素片&注射用甲苯磺酸奥马环素规格：片剂150mg、注射剂100mg适应症：社区获得性细菌性肺炎感染、急性细菌性皮肤和皮肤结构感染研发进展：小试阶段来特莫韦片&来特莫韦注射液规格：片剂240mg、480mg、注射剂240mg：12ml适应症：用于接受异基因造血干细胞移植（HSCT）的巨细胞病毒（CMV）血清学阳性的成人受者[R+]，以及肾脏器官移植后(供者CMV血清阳性/受者CMV血清阴性)的成人患者的CMV感染和CMV病的预防研发进展：原料药&制剂联合开发，验证批阶段注射用硫酸艾沙康唑&硫酸艾沙康唑胶囊规格：注射剂 372mg、胶囊剂186mg适应症：治疗成人侵袭性曲霉病和毛霉菌病，属于第三代唑类抗真菌药研发进展：原料药&制剂联合开发，完成验证批地屈孕酮片规格：10mg适应症：用于治疗内源性孕酮不足引起的疾病，如痛经、子宫内膜异位症、继发性闭经、月经周期不规则、功能失调性子宫出血、经前期综合症、先兆性流产和黄体不足所致不孕症等研发进展：原料药&制剂联合开发，中试阶段阿帕他胺片规格：60mg适应症：是首款用于治疗非转移性去势抵抗性前列腺癌及转移性去势敏感性的前列腺癌的药物研发进展：原料药&制剂联合开发，完成预BE注射用卡非佐米规格：60mg适应症：难治性多发性骨髓瘤研发进展：原料药&制剂联合申报，评审中阿贝西利片规格：50mg、100mg、150mg适应症：早期乳腺癌；局部晚期或转移性乳腺癌研发进展：原料药&制剂联合开发，中试阶段妥卡替尼片规格：50mg、150mg适应症：乳腺癌研发进展：原料药&制剂联合开发，中试阶段注射用盐酸美法仑规格：50mg适应症：多发性骨髓瘤研发进展：小试阶段磷酸芦可替尼片规格：5mg、15mg、20mg适应症：用于中危或高危的原发性骨髓纤维化（PMF）、真性红细胞增多症继发的骨髓纤维化（PPV-MF）或原发性血小板增多症继发的骨髓纤维化（PET-MF）的成年患者研发进展：完成预BE部分已有开发经验制剂品种关于上海瀚合瑞上海瀚合瑞医药科技有限公司：提供制剂项目从立项到获批的全流程药学CRO服务，具备经验丰富的的固体制剂、液体制剂和半固体制剂研发团队，以及完备的工艺和分析研发设备。截至目前，团队已完成近200个仿制药和多个创新药制剂研发服务， 多个仿制药项目取得国内首仿或前三仿。可与兄弟单位一起，为客户提供制剂和原料药研发的一站式整体解决方案，包括药学研究、临床研究（含生物等效性研究）、委托加工落户、备案登记/申报注册、MAH 持证管理、上市后技术支持等。 集团技术服务平台01制剂技术平台固体制剂、注射剂、外用制剂全流程开发难溶性药物给药技术固体分散体技术高难度复方制剂开发平台MAH合作/品种转让02原料技术平台仿制药与创新药原料药工艺开发创新工艺路线设计不对称合成、金属催化偶联、致突变杂质研究分析方法开发和验证03临床技术平台临床药代动力学生物等效性临床实验方案设计及研究运营、覆盖Ⅰ-Ⅳ期及真实世界分析检测服务联系我们1330658606013625705846↓↓扫描下方二维码免费报名关于CMC-China博览会

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the poster “Suppressing Asymptomatic CMV with Letermovir Reshapes Cardiometabolic Proteome in Treated HIV” at the Conference on Retroviruses and Opportunistic Infections (CROI 2024), in Denver, Colorado. Today’s presentation from study A5383 is the first to demonstrate that a specific inhibitor of cytomegalovirus (CMV) is safe and broadly impacts immunologic and cardiometabolic biomarkers in people living with HIV, which may explain the association between CMV and aging-related HIV co-morbidities. CMV is a chronic and usually asymptomatic virus carried by 60 percent of adults in the general population and more than 95 percent of people living with HIV. Prior to the availability of effective antiretroviral therapy (ART) for HIV, CMV caused life-threatening infections in the eyes, brain, and gut in people with compromised immune systems due to advanced HIV. While the immune system recovery resulting from ART has rendered this type of CMV organ disease rare, CMV can still affect immune responses, including inflammation, even when it is not causing obvious symptoms. “Investigators have found associations between CMV and heart disease, cancer, and other aging-related complications among people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California, Los Angeles. “Until now, however, we were unable to prove that CMV is associated with these diseases. A5383 was successful at clarifying some of the underlying mechanisms, bringing us one step closer to developing approaches to support healthy aging over the lifespan in people living with HIV.” A5383 is a phase 2, randomized, open-label, multicenter trial assessing the impact of treating people living with HIV who are virally suppressed on ART and are CMV seropositive without detectable virus in blood plasma (which means that they test positive for exposure to CMV but do not have symptoms) with letermovir, a CMV terminase inhibitor. Letermovir is CMV-specific and has no direct antiviral activity against other herpesviruses, enabling researchers to isolate the effect of CMV on the immune system. Participants in A5383 were randomized to either receive letermovir daily or no treatment for 48 weeks. A planned futility analysis (conducted to assess whether there is a low probability of the trial achieving its primary objective).after the first 39 participants completed eight weeks of therapy (N=18) or no treatment (N=21) found that instead of decreasing, the primary inflammatory endpoint (soluble tumor necrosis factor receptor 2, or sTNFR2) increased unexpectedly in the letermovir arm and the study was stopped early. To explain these findings, the team hypothesized that CMV may suppress pathways of inflammation through its immunoregulatory viral IL-10 protein, which led them to conduct a series of follow-up investigations to characterize the effects of letermovir on various inflammatory and cardiometabolic pathways in the blood. As expected, letermovir decreased IL-10 receptor signaling, which may explain the unexpected increase in sTNFR2 (essentially it took the “foot off the brakes” of the TNF pathway). Researchers found that letermovir reduced many important inflammatory pathways, including IL-1b and IL-6 receptors, which have both been causally linked to heart disease and cancer in other studies. Letermovir also improved several markers associated with atherosclerosis and endothelial dysfunction, suggesting a potential cardiovascular benefit. Metabolic pathways associated with insulin resistance also appeared to improve with letermovir. In addition, of five plasma biomarkers that were previously causally linked to heart disease in people living with HIV, three were suppressed significantly by letermovir. “While it is too soon to say whether letermovir or another anti-CMV therapy will reduce the actual risk of heart attacks, cancer, and diabetes in people living with HIV, these are exciting new data that support this therapeutic concept, which we look forward to testing in future studies,” said Protocol Chair Peter Hunt, M.D., University of California at San Francisco. “It is particularly important because we don’t yet have any treatments that are able to reduce all of these aging-related diseases in people living with HIV.” A5383 is led by Dr. Hunt and Sara Gianella, M.D., University of California San Diego (Co-Chair). ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair). It is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634. Study drugs are supplied by Merck & Co., Inc., Rahway, N.J., USA. About ACTG ACTG is the world’s largest and longest running clinical trials network focused on HIV and other infectious diseases and the people living with them. It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG conducts research to improve the management of HIV and its comorbidities; develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B, and emerging infectious diseases. It comprises thousands of dedicated researchers, staff, and community members who are pursuing research into novel treatments and cures for infectious diseases at 65 locations across four continents, with the ultimate goal of advancing science that meaningfully impacts the lives of the people we serve. Disclaimer: This content is solely the responsibility of ACTG and does not necessarily represent the official views of the NIH. Media Contact: Rachel Reiss, ACTG RLReiss@mednet.ucla.edu